logo
Select company
Select metric
$ -50.37MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
13
Sector
33
Industry
47
History
-
$ 2.41Close
$ 1.95 - $ 5.35 52-Week Range
Ticker Information

Ticker

CRDF

Company Name

CARDIFF ONCOLOGY INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

CARDIFF ONCOLOGY INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

CRDF - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 654K$ -51.02M$ -50.37M
3/31/2025$ 530K$ -48.85M$ -48.32M
12/31/2024$ 404K$ -45.43M$ -45.03M
9/30/2024$ 411K$ -42.98M$ -42.57M
6/30/2024$ 417K$ -40.86M$ -40.44M
3/31/2024$ 410K$ -40.23M$ -39.82M
12/31/2023$ 398K$ -41.44M$ -41.04M
9/30/2023$ 381K$ -40.8M$ -40.42M
6/30/2023$ 355K$ -39.64M$ -39.29M
3/31/2023$ 295K$ -38.93M$ -38.64M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • CARDIFF ONCOLOGY INC's latest trailing twelve months (TTM) EBITDA stands at $ -16.24M.
  • Over the past 5 years, CARDIFF ONCOLOGY INC's average EBITDA has been $ -35.26M.
  • The median EBITDA for CARDIFF ONCOLOGY INC during this period was $ -38.91M
  • CARDIFF ONCOLOGY INC reached its highest EBITDA over the past 5 years at $ -16.24M.
  • The lowest EBITDA recorded by CARDIFF ONCOLOGY INC in the same timeframe $ -50.37M

CARDIFF ONCOLOGY INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
MREO : MEREO BIOPHARMA GROUP PLC $ -49.23MAVTX : AVALO THERAPEUTICS INC $ -47.9MHUMA : HUMACYTE INC $ -40.8MCOYA : COYA THERAPEUTICS INC $ -21.03MVTGN : VISTAGEN THERAPEUTICS INC $ -55.12MABEO : ABEONA THERAPEUTICS INC $ 79.97MABVC : ABVC BIOPHARMA INC $ -2.42MLYEL : LYELL IMMUNOPHARMA INC $ -315.12MCURX : CURANEX PHARMACEUTICALS INC -MNPR : MONOPAR THERAPEUTICS $ -17.31M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for CARDIFF ONCOLOGY INC is calculated as follows: EBIT [ $ -16.95M ] + DepAmor [ $ 712.76K ]
(=) EBITDA [ $ -16.24M ]

CRDF - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -50.37M

Minimum

Jun 30, 2025

$ -16.24M

Maximum

Sep 30, 2020

$ -35.26M

Average

$ -38.91M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.77M with a standard deviation of $ 166.95M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.77M
median$ 8.83M
std$ 166.95M